1. first sentence of results not clear: Is fleer an IFT protein, a cargo protein or neither? Please rephrase. 2. B9d2: please cite Town et al report on stumpy in this first paragraph. 3. If Fleer binds B9d2 and Ift74 using the same domain, do B9d2 and Ift74 compete for binding. Can this competition experiment be done in a GST-pull down assay. 4. Is there a redundancy between MKS1 and B9d2? Is this the reason for the relatively mild phenotype of B9d2 single knockdown? 5. Does the fleer mutant (not the morphant) interact genetically with B9d2 and inversin? 6. In general, I cannot see any proof of knockdown of B92d, fleer and inversin -the most relevant proteins of this study. 7. Is transmission electron microscopy possible for analysis of retinal degeneration phenotypes? 7. PCP: apart from the very specific neuromast cell phenotypes, it would be good if the authors also reported on more general PCP defects such as impaired convergent extension movements. during gastrulation.
Referee #2:
This manuscript describes a biochemical and functional analysis of genes related to ciliopathies using the zebrafish. Functional analysis of the many genes that regulated ciliogenesis is an important and timely topic since cilia and basal body dysfunction underlies many different types of disease. While the work is interesting in its details, as presented it lacks focus and many of the experiments are difficult to interpret. The strength of this work is in the detailed and well controlled analysis of photoreceptor opsin transport in different cilia gene knockdowns. Other experiments don't add much to our mechanistic understanding of cilia / basal body gene function.
The paper starts by looking at interactors with the zebrafish fleer/dyf-1 protein using a 2-hybrid screen and identifies b9d2 and ift74. Unlike the mouse b9d2 mutant, knockdown of b9d2 produced no phenotype (although we don't know if the knockdown worked) so the authors pursue double knockdowns with fleer/dyf-1. Are there b9d2 paralogs in fish that mask the phenotype? Wouldn't it make sense to know whether complete loss of b9d2 (and its paralogs) functions are essential in zebrafish ciliogenesis before embarking on other studies?
The scope of the paper is then widened by searching for b9d2 interactors within the nephrocystins 1-5 (and why not 6-10?) and fleer and showing functions of various proteins in cilia localization, membrane protein transport and planar cell polarity. I find the narrative wandering. Some of the data is clearly novel and interesting but when presented this way, I am not clear that each one of the claims is fully tested/validated, particularly when most of the supporting data are based on partial double knockdowns. I do think the photoreceptor phenotype is carefully done and that alone could be the focus of a coherent paper.
Comments:
1. Validation of morpholinos knockdowns is lacking. There is no data on the efficiency of knockdown of the b9d2, inversin, fleer, ift52, or vangl2 genes. There is no data on how much morpholino was injected. RTPCR data for the NPHP5 knockdown is shown but there is no data on what kind of internal deletion is made; in frame? out of frame? There is no data on the specificity of phenotypes / off target effects. One experiment is supported by RNA rescue but many are not. Given the weight the authors would like to put on combined morpholino knockdown to validate of their proposed biochemical interactions, it would seem to be essential to know whether morpholino knockdown is complete and what constitutes partial loss of function.
2. Combined partial loss of function studies for pairs of proteins are interpreted as validating direct biochemical interactions. Strictly speaking, the results show that the proteins act in the same or parallel, non-interacting pathways to affect the endpoint. Genetically, evidence for genes acting in the same pathway would be from experiments where full loss of function for two genes did not produce a stronger phenotype than either alone.
3.DYF-1/IFT70/fleer has been previously shown to be an integral component of IFT particle complex B and essential for flagella assembly in C. reinhardtii. This work demonstrated a biochemical interaction of DYF-1/IFT70 with IFT46. The authors don't seem to have acknowledged this work or tested IFT46 as a candidate interactor. How do IFT protein interactions fit with data from other species?
4. IFT transport of dyf-1/fleer has been previously shown using GFP fusions in C. elegans. More specific functions of dyf-1/fleer gene have been reported in the regulation of axonemal tubulin glutamylation. What is the role of the putative interacting proteins identified in this paper in tubulin glutamylation?
5. The authors state that fleer mutants show a clear loss of cilia although this was not the phenotype of the fleer mutant described by Pathak et al. Neuromast cilia are shortened but present as are single cilia in the pronephros of fleer mutants.
6. Figure 2F is shown to support the claim that GFP:B9d2 is expressed specifically in cilia. Expression is clearly cytoplasmic as well, raising the concern that cilia localization could be due to diffusion (despite the GFP control) as opposed to targeting. The specificity of this results is a concern since immunostaining for a mouse b9d2 ortholog shows it specifically in basal bodies (and not cytoplasm or cilia).
7. On page 8, data is presented on a curled body phenotype and situs inversus. In neither case are the cilia responsible directly examined. What accounts for the curled body phenotype? Are nodal cilia affected?
Referee #3:
In the manuscript by Zhao and Malicki they evaluate interactions between IFT, MKS related B9 protein and show that it is required for localization of another ciliary component Inv(nhp2). They identified binding partners of Fleer and then tested functional interactions in ZF through subeffective doses of MO and analyzed the effect on three cilia related phenotypes -LR axis, curly tail, and opsin transport. They show that B9D2 and INV, IFT52, Flr, NPHP5 are functionally related and are needed for normal cilia formation, opsin transport in the photoreceptor cells and for regulation of normal planar cell polarity. Overall the data are convincing and address an important area, but there remain several areas where additional experiments and controls should have been included to make the article acceptable for EMBO.
The authors need to be more consistent in the nomenclature of the various genes and proteins that are studied. For example, in supplemental figure 1, murine B9d2 is referred to as stumpy, a Tza-1 in C. elegans is incorrectly called Taz-1. Do they see similar synergistic effects when they combine MO with a non-IFT related ciliary gene (e.g. polycystin). In other words, how specific is this observation. Their studies with co-injection of BBS4 do begin to address this, but the connection of the BBSs to IFT in fish is still unclear (BBS7 and 8 in C. elegans). A major concern is the lack of RT-PCR and/or Western blots demonstrationg successful and specific knockdown of targeted genes is being achieved as well as rescue of any phenotypes. This needs to be shown for all morpholinos used and not just nphp5 in supplemental figure 4. This is particularly relevant in the b9d2 MO where they indicate that even high levels of MO did not cause a phenotype. One concern is that their interaction data are based only on in vitro data (Y2H or purified proteins) and most of these were found to be mediated through the N-terminal region of Fleer. Is it possible this represents a "sticky" region of the protein that binds to common structure or motif in the target proteins? Also the authors suggest in their model (figure 8) that these data indicate that these proteins form a complex, but they provide no data as to whether these interactions are mutually exclusive. Thus, exploring the interactions in a more biologically relevant cell culture system would strength their claim and would also provide insights into whether they actually form a large mutliprotein complex. They make an argument that since RDS localization in the outer segment is not affected by partial KO of IFT and thus its transport must be different than that seen for opsin. Have the authors tested opsin transport under these conditions where IFT is only partially impaired? The authors show interactions between Vngl, b9d2, flr, and invs in establishing PCP and extrapolate their findings to the IFT88 mutant mouse PCP defect. In the IFT88 mutant, the PCP phenotype does not alter localization of the PCP core proteins, but rather affects transport or localization of the basal body to the correct spot in the cell. If the authors are arguing that this is the basis of their MO knockdown mutants they should have analyzed whether these are disrupted in their models as well.
Specific Comments:
Figure 1: The nomenclature of proteins in the figure title and texts indicate that zebrafish Fleer binds Ift52 and B9d2, however the figure legend itself makes clear that human cDNA was used to make these constructs. Figure 2 : The inclusion of standard deviations in the graphs of this figure are appreciated, but there is no mention of if the double morphants have a statistically significant difference from the control. The data in figure 2F need to be further explained. How is acetylated tubulin -shown with an antibody-only observed in two cells? Is acetylated tubulin only present in ciliated cells? Also the BPD2-EGF signal is particularly weak and is not markedly different than what is seen in the cytosol. Further faint GFP alone signal can be seen in the cilium raising concerns as to what they are actually analyzing. Are the authors confident that this is specific for the fusion protein? Figure 4 : The legend to this figure needs to more explicitly state the difference between the red and blue bars in figure 4D , and why both are included. A minor critique is in figure 4C , where the "c" in "cMO" should be capitalized to be consistent with the other figures. Referee #1: fig. S5 .
Does the fleer mutant (not the morphant) interact genetically with B9d2 and inversin?
Yes, the fleer mutant does interact genetically with B9d2. We present these data in Fig. S4C .
6. In general, I cannot see any proof of knockdown of B92d, fleer and inversin -the most relevant proteins of this study.
We did not provide standard controls for the efficiency and specificity of fleer and inversin knockdowns because these experiments were presented in previous publications: Otto et al. Nature Genetics v. 34, p. 418, 2003 (for Inversin), and Pathak (Mol. Bio. of the Cell, v. 18, p. 4357(for fleer figure S6D and E.
8. PCP: apart from the very specific neuromast cell phenotypes, it would be good if the authors also reported on more general PCP defects such as impaired convergent extension movements. during gastrulation.
We have not observed obvious synergy between vangl and b9d2 knockdowns during convergent extension. Similarly, we have not observed obvious synergy between b9d2 and inversin and/or diversin. We mention this result briefly in the revised manuscript.
Referee #2:
We now addressed these questions as explained in response to reviewer 1.
In the studies of the b9d2 phenotype, we now monitor knockdown efficiency using a reporter construct as explained in the response to reviewer 1. For the remaining genes, the null loss of function phenotypes were published as follows : inversin, Otto et al., 2003; fleer, Pathak et al., 2007; ift52, Tsujikawa and Malicki, 2004; vangl2, Jessen et al., 2002, Lopez-Schier and Hudspeth, 2006 . It was not then our goal to repeat these studies and demonstrate null phenotypes. Except for knockdowns B9 domain genes shown in Fig. S5A 6. Figure 2F is shown to support the claim that GFP:B9d2 is expressed specifically in cilia. Expression is clearly cytoplasmic as well, raising the concern that cilia localization could be due to diffusion (despite the GFP control) as opposed to targeting. The specificity of this results is a concern since immunostaining for a mouse b9d2 ortholog shows it specifically in basal bodies (and not cytoplasm or cilia).
Immunostaining for the mouse b9d2 ortholog, stumpy, shows that it localizes to cilia (Town et al., PNAS, Fig. 4D). The authors of this work write in the figure legend "Note stumpy signal at the bb (Left, see arrowhead) and ciliary axoneme". Our results are thus in agreement with these observed in the mouse.

We quantitated the ratio of GFP signal in cilia vs. the cytoplasm at the base of cilia for GFP and B9D2-GFP expression. This ratio is clearly lower in GFP expressing animals (p<0.001). We present this result in the revised version (Fig. S4D). Please note also that the cilium is a very thin structure (ca. 200 nm in diameter) and so the strength of the cytoplasmic signal tends to be exaggerated.
It is well known that the curly body phenotype is present in many zebrafish ciliary mutants. We are not aware, however, of any explanation for this phenotype in literature.
The authors need to be more consistent in the nomenclature of the various genes and proteins that are studied. For example, in supplemental figure 1, murine B9d2 is referred to as stumpy, a Tza-1 in C. elegans is incorrectly called Taz-1.
We changed the nomenclature in fig. S1 as requested.
Do they see similar synergistic effects when they combine MO with a non-IFT related ciliary gene (e.g. polycystin). In other words, how specific is this observation. Their studies with co-injection of BBS4 do begin to address this, but the connection of the BBSs to IFT in fish is still unclear (BBS7 and 8 in C. elegans).
We have performed control double knockdowns with anti-pkd2 morpholino as suggested by the reviewer. We see no genetic interaction between pkd2 and b9d2. There is a synergy between pkd2 and inversin knockdowns, but the frequency of mutant phenotype in double morphants is very low (ca. 8 x lower), compared to an experiment in which the same amount of anti-inversin morpholino is used to test interaction with b9d2. The concentration of the anti-pkd2 morpholino that we used in this experiment was sufficient to induce body curvature defects. We present these data in Fig. S6G.
A major concern is the lack of RT-PCR and/or Western blots demonstrating successful and specific knockdown of targeted genes is being achieved as well as rescue of any phenotypes. This needs to be shown for all morpholinos used and not just nphp5 in supplemental figure 4. This is particularly relevant in the b9d2 MO where they indicate that even high levels of MO did not cause a phenotype.
We addressed this criticism as explained in response to reviewer 1. To monitor the efficiency of the b9d2 knockdown, we used a reported construct.
One concern is that their interaction data are based only on in vitro data (Y2H or purified proteins) and most of these were found to be mediated through the N-terminal region of Fleer. Is it possible this represents a "sticky" region of the protein that binds to common structure or motif in the target proteins?
To address this concern, we tested the N-terminal region of Fleer against 10 other proteins. Only one of these showed a weak interaction, which was not confirmed when bait and pray were switched. We comment on this result in the text of the revised manuscript, and present relevant data in Fig. S2 .
Also the authors suggest in their model (figure 8) that these data indicate that these proteins form a complex, but they provide no data as to whether these interactions are mutually exclusive. Thus, exploring the interactions in a more biologically relevant cell culture system would strength their claim and would also provide insights into whether they actually form a large mutliprotein complex. Fig. 5 .
To address this important concern, we tested whether three proteins, each from a different functional category (at least by the criteria of human phenotype), can simultaneously bind each other. We used a Nephrocystin (Inversin), an MKS protein (B9d2), and an IFT protein (Fleer). As explained in the response to reviewer 1, these three proteins simultaneously bind each other, and
B9d2 is necessary to mediate binding interaction of Inversin with Fleer (repeated 4 times)(Fig. 5E). We chose to perform this experiment in vitro as this shows that no other polypeptides are necessary to mediate these binding interactions. We believe that the functional relevance of these binding interactions in vivo is demonstrated by genetic experiments presented in
They make an argument that since RDS localization in the outer segment is not affected by partial KO of IFT and thus its transport must be different than that seen for opsin. Have the authors tested opsin transport under these conditions where IFT is only partially impaired?
Yes, we have performed this experiment. Even when opsin localization is clearly affected, the localization of peripherin is not. We indicate this result in the revised manuscript.
The authors show interactions between Vngl, b9d2, flr, and invs in establishing PCP and extrapolate their findings to the IFT88 mutant mouse PCP defect. In the IFT88 mutant, the PCP phenotype does not alter localization of the PCP core proteins, but rather affects transport or localization of the basal body to the correct spot in the cell. If the authors are arguing that this is the basis of their MO knockdown mutants they should have analyzed whether these are disrupted in their models as well. Specific Comments:
Figure 1: The nomenclature of proteins in the figure title and texts indicate that zebrafish Fleer binds Ift52 and B9d2, however the figure legend itself makes clear that human cDNA was used to make these constructs.
We now indicate in the manuscript text that human homologs of fleer and B9d2 were used in these experiments. . We now provide this information in Fig. 2 legend.
The data in figure 2F need to be further explained. How is acetylated tubulin -shown with an antibody-only observed in two cells? Is acetylated tubulin only present in ciliated cells? Fig. 2 legend.
Acetylated tubulin is present at a high level in the cytoplasm of so-called tether cells (presumably hair cell precursors). We indicate this now in
Also the BPD2-EGF signal is particularly weak and is not markedly different than what is seen in the cytosol. Further faint GFP alone signal can be seen in the cilium raising concerns as to what they are actually analyzing. Are the authors confident that this is specific for the fusion protein?
To address this concern we quantitated the ratio of signal intensity in the cilium vs. the cytosol for GFP and B9d2-GFP (n≥ 10 for each group). We observe a marked difference between these two constructs (p < 0.001). Please see also our response to reviewer 2.
Figure 4: The legend to this figure needs to more explicitly state the difference between the red and blue bars in figure 4D , and why both are included.
We now explain the meaning of red and blue bars in Fig. 4 legend. A minor critique is in figure 4C , where the "c" in "cMO" should be capitalized to be consistent with the other figures
We corrected this figure as suggested. I did receive comments from one of the original referees.
This scientist remains unconvinced from the more general function of b9d2 in IFT, at least based on the evidence currently provided. At the same time, this expert emphasizes the high quality of the photoreceptor work and appreciates significant adjustments during initial revision.
To accommodate his/her criticisms, I suggest emphasizing the most convincing (photoreceptor) findings first before proposing potential more general roles in IFT as shown by mostly genetic data. Fully aware that you already addressed the cilia-localization issue of b9-proteins, additional evidence would be appreciated to diffuse these concerns. I also ask you to consider presentation of the cilia-length phenotype and specify actual amount of morpholinos injected. Overall, there is still support for publication in The EMBO Journal. I am thus able to offer submission of an appropriately amended, ultimate version of your paper.
Yours sincerely,
Editor
The EMBO Journal REFEREE REPORTS:
The authors have done additional experiments and have clearly put alot of effort into revising this work. Nonetheless parts of the data remain unconvincing and and some previous concerns raised remain unaddressed.
A current goal in the field of ciliogenesis is determining which of the 600 or so proteins that make a cilium function together in cilia sub-assemblies and then determining what these sub-assemblies do.
A strength of this work is the biochemistry and the delineation of protein interactions. I think this work partially answers some questions by defining a protein sub-assembly and this moves the field forward. However data supporting the function of the sub-assembly in vivo remains unclear and unconvincing.
The authors acknowledge that genetic interactions do not really indicate direct interaction but still give undue significance to the augmentation of cilia phenotypes induced by combined knockdown of fleer or ift52 with b9d2 morpholinos. These phenotypes were not observed with b9d2 knockdown alone and subject to interpretation bias. To illustrate, the yeast two hybrid analysis categorically indicates no direct interaction between IFT52 and b9d2, yet this is indicated genetically by the axis curvature defects summarized in Fig. 4A . Since the focus here is on Fleer, the authors immediately interpret this as revealing fleer-b9d2 interactions. Perhaps more negative controls should have been evaluated with other components of the IFT-B complex.
Perhaps least convincing are the conclusions the authors wish to draw from transgenic expression of GFP fusion proteins. The concern that cilia localization of b9d2:GFP could be due simply to diffusion that was raised in my previous review has not been addressed. Soluble GFP expressed in the cytoplasm can easily diffuse into cilia. The fact that b9d2:GFP is strongly expressed in the cytoplasm as well as in cilia suggests that its localization is not specific to cilia; that it is just diffusing into cilia. This and the existing body of work in other organisms showing that b9 proteins are basal body proteins (not in cilia axonemes or in cytoplasm) further suggests that the b9d2:GFP localization in cilia reported here is not specific and may be the result of overexpression. While it is true that the cilium is a very thin structure (ca. 200 nm in diameter), this does does not impede the use of reporters like arl13b:GFP which show axoneme-specific expression. To bolster their claims of cilia-specific localization of fusion proteins, the authors present a GFP expression only control. But according to their methods, they are using 3 to 4 fold less plasmid transgene for the control than the experimental fusion constructs. The rationale for this (normalizing protein amount) is not clear since all the proteins are expressed from the same promoter and this approach could lead to enhanced expression of fusion proteins vs. control and hence diffusion into cilia. Without specific subcellular localization of fusion proteins, the data is not meaningful. This criticism applies to the inversin:GFP work as well.
On the other hand the work on photoreceptors using an opsin GFP fusion are clean and informative.
Photoreceptors are the only tissue that show a b9d2 knockdown phenotype. A focused paper on photoreceptor or other sensory cilia (vs. motile cilia) phenotypes would be stronger than the current manuscript. Although triple knockdown of b9 proteins did not affect motile cilia length, it might produce a fully penetrant photoreceptor phenotype compared to b9d2 knockdown alone; this was not examined.
Other Comments:
Why are cilia length measurements always reported in %? Percent of what? What does it mean if controls have 120% cilia length? Cilia length in microns should be reported.
The amounts of morpholinos used is still vague; 2 µg/µl is a concentration; how much was injected? Or is this the calculated final cytoplasmic concentration?
In the double knockdown of b9d2 and fleer in spinal canal and olfactory cilia, the authors say cilia length is reduced. In kinocilia, length is unaffected by double knockdown. b9d2 cannot have a central role in IFT.
The planar cell polarity figure seems tacked on at the end with little examination of mechanism. We are pleased to submit the second revision of the manuscript titled "Nephrocystins and MKS Proteins Interact with the IFT Particle and Facilitate Transport of Selected Ciliary Cargos". In response to your suggestions, we introduced the following changes:
1. To emphasize photoreceptor findings, which reviewer 2 and yourself find to be particularly convincing, we now present photoreceptor data before the data on genetic interactions in other organs. This resulted in a change of the sequence of figures. Figure 6 is now presented as Figure 4 , and vice versa, former Figure 4 is now presented as Figure 6 . There also corresponding changes to supplementary figures. We also modified the title by adding "Selected Ciliary Cargo" to emphasize that the mechanism that we present most likely applies to some cilia only. To diffuse concerns regarding the role of B9D2 in ciliogenesis, we modified the relevant section of the discussion. We now state that B9D2 function is likely to vary in different classes of cilia.
2. To provide additional evidence that B9d2 localizes to cilia, we repeated B9d2 localization experiments with two additional controls. In addition to B9d2 and GFP-B9d2, we also expressed centrin-GFP and elipsa-GFP. Elipsa is an IFT particle component, and thus it is expected to localize to cilia, while centrin is a basal body component and should not localize to cilia. This is, in fact, what we see (repeated twice). We present these results in the Fig. 2G and Fig. S4D of the revised manuscript. These additional data further strengthen our claim that B9d2 does localize to cilia.
We would like to make two additional comments regarding the ciliary localization of B9d2. First, the reviewer writes again "This and the existing body of work in other organisms showing that b9 proteins are basal body proteins… " He/she ignores our explanations (in the response to the first round of review) that the mouse B9d2 also localizes to the ciliary shaft (Town et al., 2008, PNAS, Fig. 4D) . It is true that b9d2 and related proteins localize to the basal body in C. elegans, but the mouse data is in agreement with our results. Moreover, in recent studies of mammalian cells B9 proteins also localize to cilia (Bialas et al., JCS, 2009, Fig. 2B) . Why is the reviewer convinced then that "…b9 proteins are basal body proteins.."?
Second, and more importantly, the reviewer misunderstood the methods section. The reviewer writes that "…according to their methods, they are using 3-to 4-fold less plasmid transgene for the control… ". The methods section of the original manuscript states that in the case of B9d2 experiments, we use RNA overexpression, not plasmids. Consequently, the above concern does not apply to B9d2 expression studies. To clarify this further, in the most recent set of experiments we used twice as much GFP as GFP-B9d2 (data presented in Fg. 2G). We provide information on RNA concentration in the methods section of the revised manuscript.
In the case of Inversin studies, we did use a plasmid and the reviewer is correct that we use a lower concentration of the control plasmid. This is not a concern, however, as the intensity of cytoplasmic GFP signal is still the highest in GFP-only control cells. We now present this data in Fig. S7B . Second, we are comparing signal intensity in the cilium to that in cell's cytoplasm. Consequently, the result that we present is a ratio of intensities, and thus the initial plasmid concentration is of little relevance as it is unlikely to affect this ratio (it is likely to affect absolute values, but not the ratio). Finally, the purpose of this experiment is to compare control animals to individuals treated with anti-b9d2 morpholino (these two groups are injected with the same plasmid concentration). If the presence of b9d2-GFP in the cilium was a consequence of an overexpression artifact, the intensity of b9d2-GFP signal in the ciliary shaft would not differ between control and anti-b9d2 morpholino-treated animals. This is not the case.
3. Finally, we introduced several other changes that you requested. We now specify the lengths of cilia in the control sample (which equals 100%) in micrometers in the legend to each figure. We use standard protocols to perform morpholino injections. We do not measure the volume that we inject, we do, however, use the same conditions (injection pressure and duration, needle size, etc.) to perform injection of animals in control and experimental groups. We mention this briefly in the supplementary methods section of the revised manuscript. The concentrations of all morpholinos are also provided in Table S1 .
To shorten the manuscript a bit, we deleted several non-essential statements from the results and discussion sections. Apart from minor stylistic changes, all alterations introduced for the first time in this version of the manuscript are in blue type.
We hope that you will find the revised manuscript satisfactory and look forward to a positive decision regarding its publication. We thank you for your time and effort.
